Initial Real-World Evidence for Lecanemab in the United States

Area of Science:

• Neurology
• Pharmacology
• Clinical Research

Background:

• Lecanemab is the first fully approved anti-amyloid monoclonal antibody for early Alzheimer's disease (AD).
• Real-world data on lecanemab utilization patterns are crucial for understanding its implementation.

Purpose of the Study:

• To analyze patient demographics, clinical characteristics, provider specialties, and lecanemab utilization.
• To identify patterns in lecanemab treatment initiation and continuity.

Main Methods:

• Observational study utilizing administrative claims data from PurpleLab.
• Included 4261 patients receiving lecanemab between January 2023 and October 2024.
• Analyzed demographics, clinical data, and treatment gaps for up to 6 months prior to infusion.

Main Results:

• The study population (n=4261) had a mean age of 75.2 years, predominantly White (77.8%) and urban (98.4%) residents.
• Most patients (81.7%) were treated by neurologists, with 77.3% having diagnosed AD.
• Lecanemab infusions averaged 1.9 per patient monthly, with 2.8% experiencing interruptions ≥90 days.

Conclusions:

• Lecanemab utilization generally aligned with FDA prescribing guidelines.
• Observed disparities in access for minority and rural populations highlight areas for improvement.